Pradžia › Alfa-1 antitripsino trūkumas › Texas
Alfa-1 antitripsino trūkumas klinikiniai tyrimai Texas
4 tyrimai dėl Alfa-1 antitripsino trūkumas ieško dalyvių vietose Texas.
Oficialus tyrimo tekstas (anglų kalba)
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
- GC2501 Study Site 109, Dallas
Renkami dalyviai3 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-08-11 · NCT07555483Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
- Texoma Liver Center, Denison
- Baylor College of Medicine Medical Center, Houston
- The Texas Liver Institute, San Antonio
Renkami dalyviai3 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-05-13 · NCT05677971Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
- Texas Liver Institute American Research Corporation, San Antonio
Renkami dalyviai3 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-03-05 · NCT06165341A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
- Renovatio Clinical, The Woodlands
Renkami dalyviai1 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2025-07-22 · NCT06049082Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.